Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 6,033

Document Document Title
WO/2012/142671A1
The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of th...  
WO/2012/140251A1
The invention relates to a rubber composition for the production of tyres, containing one or more diene elastomers, one or more reinforcing fillers and a vulcanisation system. The composition is characterised in that the vulcanisation sy...  
WO/2012/138734A1
In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula : (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said ...  
WO/2012/126570A1
The invention relates to combinations having at least one bicyclic or tricyclic ring system, which is connected by acetylene ethylene or difluoroethylene bridges, to the application thereof in high frequency components, to liquid crystal...  
WO/2012/121168A1
The purpose of the present invention is to provide: a novel compound having an excellent CK2-inhibiting activity and high safety; and use applications of the compound. Provided are: a CK2 inhibitor comprising, as an active ingredient, a ...  
WO/2011/107283A3
The invention relates to a composition comprising taurolidine and/or the hydrolysis products thereof and also a biodegradable (co)polymer or inorganic matrix for use as an implant for treating local infections of the skeleton and soft ti...  
WO/2012/082893A2
High performance organic photovoltaic cells based on donor acceptor polymers in the active layer. A composition comprising: at least one copolymer comprising at least one first donor moiety and at least one first acceptor moiety in the c...  
WO/2012/079164A1
The present invention is directed to activators of cylindrical proteases ("ACPs"), particularly ClpP, and the role thereof in the diagnosis and treatment of bacterial infections. A number of ACPs were identified that activate caseinolyti...  
WO/2012/050484A3
The invention relates to organic chemistry, more specifically to novel biologically active compounds in the form of 5-amino-1,2,4-thiadiazole derivatives of general formula (I), where X may be ONO2 or NHR3; R1, R2, R3 may be the same or ...  
WO/2012/077478A1
Aspects of the present invention can provide a novel phenanthrothiadiazole compound with the lowest excited triplet level T1 that is high, the phenanthrothiadiazole compound being capable of forming a stable amorphous film. Furthermore, ...  
WO/2012/070066A1
The present invention relates to a process for the preparation of substantially pure Taurolidine.  
WO/2012/029032A3
The present invention relates to heterocyclic compounds of Formula (1), in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides...  
WO/2012/062210A1
The compound of formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complex thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The...  
WO/2011/162514A3
The present invention provides a novel method for preparing [1,2,3]-oxathiazolidine-2,2-dioxide or [1,2,5]-thiadiazolidine-1,1-dioxide derivatives. According to the manufacturing method of the present invention, it is possible to conveni...  
WO/2012/050484A2
The invention relates to organic chemistry, more specifically to novel biologically active compounds in the form of 5-amino-1,2,4-thiadiazole derivatives of general formula (I), where X may be ONO2 or NHR3; R1, R2, R3 may be the same or ...  
WO/2012/006104A3
The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus, and thus are useful in the treatment of tuberculosis infection and associated conditions. Th...  
WO/2012/046869A1
[Problem] To provide a GPR40 activator, particularly an insulin secretion stimulator or a prophylactic and/or therapeutic agent for diabetes, obesity or the like, which contains a novel compound having a GPR40 agonistic activity, a salt ...  
WO/2012/012307A9
Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which ...  
WO/2012/004714A3
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...  
WO/2012/025638A1
The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.  
WO/2012/019998A1
The invention relates to different methods for producing N'-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl] oxy} -2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide.  
WO/2012/013728A1
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a...  
WO/2011/152471A3
Provided is a rechargeable battery with a higher degree of safety. Specifically provided is a rechargeable battery constituted so as to prevent overcharging. The rechargeable battery is a battery which uses a positive electrode material ...  
WO/2012/012307A1
Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which ...  
WO/2012/004714A2
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...  
WO/2012/006104A2
The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus, and thus are useful in the treatment of tuberculosis infection and associated conditions. Th...  
WO/2011/162514A2
The present invention provides a novel method for preparing [1,2,3]-oxathiazolidine-2,2-dioxide or [1,2,5]-thiadiazolidine-1,1-dioxide derivatives. According to the manufacturing method of the present invention, it is possible to conveni...  
WO/2011/156655A2
Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for u...  
WO/2011/152471A2
Provided is a rechargeable battery with a higher degree of safety. Specifically provided is a rechargeable battery constituted so as to prevent overcharging. The rechargeable battery is a battery which uses a positive electrode material ...  
WO/2011/076784A3
The present invention relates to a compound of formula (I): Formula (I), wherein: - n is 0, 1 or 2; - A is in particular CH or N; - X is in particular CO, SO2, CS, and R1 is in particular H, - R2 is a group of formula NR3R4 or OR5, R3 an...  
WO/2011/082400A3
Disclosed are an assay to identify modulators of the PD-1 :PD-L pathway and PD-1 :PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1 :PD-L ...  
WO/2011/132712A1
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...  
WO/2011/069045A3
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.  
WO/2011/070177A3
Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, ...  
WO/2011/082941A1
The present invention relates to benzyl-substituted thiadiazolyl oxyphenyl amidinium salts of the general formula (I), to a method for the production thereof, to the use of the amidinium salts according to the invention for combatting un...  
WO/2010/149578A3
Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 a...  
WO/2011/083265A1
The invention relates to compounds of formula (I): where R1 and R2, identical or different, each represent a hydrogen or halogen atom or a cyano, hydroxyl, thio, nitro, alkyl, alkoxy, alkylthio, carboxy, alkoxycarbonyl, acyloxy, amino, a...  
WO/2011/082400A2
Disclosed are an assay to identify modulators of the PD-1 :PD-L pathway and PD-1 :PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1 :PD-L ...  
WO/2011/070177A2
Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, ...  
WO/2011/039554A3
The present invention relates to compounds 2,3,4-benzothiadiazepine-2,2-dioxide derivatives and enantiomers of the general Formula (I) wherein 'a' represents single or double bond, R1 and R2 represent, independently, hydrogen, halogen, c...  
WO/2011/069647A1
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: wherein:. L represents a direct bond or a -S(O)2- group, • n is an integer having a value from 0 to 2, • R1 represe...  
WO/2011/071095A1
Disclosed is a compound which is useful as a GK activator. Studies have been made on compounds which have a GK activating action and are therefore promising as active ingredients of pharmaceutical compositions for the treatment of diabet...  
WO/2011/069045A2
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.  
WO/2011/061110A1
The invention relates to alkylsulfide derivatives compounds of formula I as hererunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular a...  
WO/2010/149598A3
Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.  
WO/2011/059042A1
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...  
WO/2011/054947A1
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: R1 is C1-3alkyl or C1fluoroalkyl-CH2; R2 is hydrogen, C1-4alkyl, C1fluoroalkyl-CH2-, C3-6cycloalkyl, C3-6cycloalkyl-methyl-, optional...  
WO/2011/052727A1
Disclosed is a compound which has a light absorption end wavelength that is a long wavelength. Specifically disclosed is a compound which contains a structural unit represented by formula (1). (In the formula, Ar1 and Ar2 each represents...  
WO/2011/049531A1
The invention provides organic compounds of formula I, wherein each A is an independently selected conjugated electron withdrawing aromatic or heteroaromatic group; each D is an independently selected ethenylene group, ethynylene group o...  
WO/2011/046954A1
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...  

Matches 251 - 300 out of 6,033